iPS-AF091

General

Cell Line

hPSCreg name HNMUi010-A
Cite as:
HNMUi010-A (RRID:CVCL_A1CG)
Alternative name(s)
iPS-AF091
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
HNMUi004-A
(iPS-AF717)
Donor diseases:
Thalassemia
HNMUi007-A
(iPS-AF0442)
Donor diseases:
Thalassemia
HNMUi003-A
(iPS-UC1290)
Donor diseases:
Thalassemia
HNMUi006-A
(iPS-UC1055)
Donor diseases:
Thalassemia
HNMUi009-A
(iPS-UC1171)
Donor diseases:
Thalassemia
HNMUi005-A
(iPS-UC1056)
Donor diseases:
Thalassemia
HNMUi008-A
(iPS-UC2419)
Donor diseases:
Thalassemia
HNMUi002-A
(iPS-UC1291)
Donor diseases:
Thalassemia
Last update 22nd September 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Hainan Medical University (HNMU)
Owner Hainan Medical University (HNMU)
Distributors
Derivation country China

External Databases

BioSamples SAMEA7484346
Cellosaurus CVCL_A1CG
Wikidata Q102114141

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex female
Age of donor (at collection) fetal
Ethnicity Chinese Han

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
Thalassemia major
Synonyms
  • α- and β-thalassemia
  • sickle-cell thalassemia without crisis
  • thalassemia
  • sickle-cell thalassemia with crisis
  • thalassemia Hb-S disease without crisis
  • thalassemia Hb-S disease with crisis
show more synonyms
Genetic variants
HBB/11p15.4
βCD41-42/βCD41-42(HBB: c. 124_127delTTCT)
Homozygous
Disease associated phenotypes no phenotypes

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46,XX

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA7484347

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. Ping Long(Email:1071545806@qq.com)
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Ping Long(Email:1071545806@qq.com)
Has the donor agreed to be re-contacted? Unknown
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? The First Affiliated Hospital of Hainan Medical University
Approval number 2017-KY-001
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? The First Affiliated Hospital of Hainan Medical University
Approval number 2017-KY-001
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Fluid within the amniotic cavity produced by the amnion during the early embryonic period, and later by the lungs and kidneys; at first crystal clear, it later becomes cloudy. It protects the embryo and fetus from injury. The amount at term normally varies from 500 to 1500 mL.
Synonyms
  • acqua amnii
  • liquor amnii
Age of donor (at collection) fetal

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
Immunostaining, RT-PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
NANOG
Yes
TRA 1-60
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)